Email

weisheng.lu@bcm.edu

Positions

Postdoctoral Associate (Feb 2024 - now)

Pediatrics - Nutrition
Baylor College of Medicine
Houston, US

Addresses

Children's Nutrition Research Center (Office)

1100 BATES
Room 8062
Houston, TX, 77030
United States

Children's Nutrition Research Center (Lab)

1100 BATES
Room 8052
Houston, TX, 77030
United States

Education

PharmD from China Pharmaceutical University

06/2021 - Nanjing, Jiangsu, China

BS from China Pharmaceutical Univeristy

06/2015 - Nanjing, Jiangsu, China

Websites

Selected Publications

• Hsiao-Yun Lin†, Weisheng Lu†, Yanlin He, Yukiko Fu, Kentaro Kaneko, Peimeng Huang, Ana B. De la Puente-Gomez, Chunmei Wang, Yongjie Yang, Feng Li, Yong Xu, Makoto Fukuda*. " Low-dose metformin requires brain Rap1 for its antidiabetic action " Sci Adv. 2025 Jul 30; 11 (31) : eadu3700.
  Pubmed PMID: 40737402.
• Kentaro Kaneko†, Weisheng Lu†, Yong Xu, Alexei Morozov, Makoto Fukuda*. " The small GTPase Rap1 in POMC neurons regulates leptin actions and glucose metabolism " 2025 Feb 28; 102117
  Pubmed PMID: 40024570.
• Weisheng Lu†, Hong Tian†, Peng Qian, Ying Li, Yongkang Wang, Yang Ge, Wenbo Sai, Xiangdong Gao*, Wenbing Yao*. " An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice " Br J Pharmacol. 2020 Apr 15; 177 (15) : 3473-3488.
  Pubmed PMID: 32293707.
• Teng Ma, Weisheng Lu, Yongkang Wang, Peng Qian, Hong Tian, Xiangdong Gao*, Wenbing Yao*. " An oral GLP-1 and GIP dual receptor agonist improves metabolic disorders in high fat-fed mice " Eur J Pharmacol. 2022 Jan 5; 914 (174635)
  Pubmed PMID: 34800466.
• Peng Qian†, Hong Tian†, Yongkang Wang, Weisheng Lu, Ying Li, Teng Ma, Xiangdong Gao*, Wenbing Yao*. " A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction " Biochem Pharmacol. 2020 Dec ; 182 (114209)
  Pubmed PMID: 32860826.

Show 1 more publications

Intellectual Property

Oral hypoglycemic peptide, fatty acid derivative and use thereof

Design Patent #WO2021027762A1 (Approved)

Provided in the present invention are an oral hypoglycemic polypeptide, fatty acid modified derivatives thereof, and uses of the polypeptide and the fatty acid modified derivatives thereof.

Co Inventors: GAO Xiangdong, TIAN Hong, LU Weisheng, YAO Wenbing, SAI Wenbo

Languages

Chinese (Mandarin), Japanese